Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
Redhill Biopharma has claimed success with its novel Crohn's disease therapy, but there is more to this "victory" than meets the eye.
TG and Redhill are expecting phase III data soon, but both have a fight ahead to make their mark even if their projects succeed.